CHATIL 101
Alternative Names: CHATIL-101Latest Information Update: 31 Mar 2025
At a glance
- Originator CHA Bio & Diostech
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Solid tumours
Most Recent Events
- 12 Mar 2025 Clinical trials in Solid tumours (Parenteral) before March 2025 (CHA Bio & Diostech pipeline, March 2025)
- 12 Mar 2025 Preclinical trials in Solid tumours in South Korea (Parenteral) before March 2025